FDA Accepts Supplemental Application for Diacomit (Stiripentol)
The FDA has accepted a supplemental application for Diacomit (stiripentol) submitted by Biocodex SA.
Asset / Drug
Drug and asset intelligence for Diacomit with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.